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Abstract
Introduction Chronic Obstructive Pulmonary Disease
(COPD) is a chronic, progressive disease that is not cur-
able. However, there are effective treatments available. In
the UK, long-acting bronchodilators are first-line treat-
ments for COPD patients requiring maintenance therapy,
and there are several options available. The aim of this
study is to establish, from the UK National Health Service
(NHS) perspective, the cost-effectiveness profile of ind-
acaterol, the first once-daily long-acting beta2-agonist
(LABA), compared with tiotropium and salmeterol, in
patients with moderate to severe COPD. In assessing the
cost-effectiveness of COPD therapies, this study has the
advantage of using real world evidence on the resource use
associated with COPD management across the spectrum of
the disease.
Methods A Markov model was developed with four
health states following the GOLD classification for severity
of airflow limitation. The model time horizon was 3 years,
and the cycle length was 3 months. From each state,
patients could experience a severe or non-severe exacer-
bation, move to a different COPD state, remain in the
current state or die. Transition probabilities were based on
data from the indacaterol clinical trials. The majority of the
resource use data was taken from the Optimum Patient
Care Research Database (OPCRD), which contains data
from over 20,000 COPD patients in England and Scotland.
Cost data were taken from UK-based sources and published
literature and presented for the cost year 2011. Health-
related quality of life was the main outcome of interest and
utility data for the COPD states were based on data from
the indacaterol clinical trials and disutility due to exacer-
bations were taken from the literature. Both one way and
probabilistic sensitivity analyses were performed to test the
robustness of the results.
Results Indacaterol dominated in the comparison with
salmeterol producing an incremental QALY gain of 0.008
and cost savings of £110 per patient over a 3-year time
horizon. In the comparison with tiotropium over the same
time horizon, indacaterol remained the dominant strategy,
producing an incremental QALY gain of 0.008 and cost
savings of £248 per patient. The one-way sensitivity
analysis indicates that the proportion of patients in each of
the COPD stages and the mortality rate associated with
Very Severe COPD are the variables with the largest
impact on the results. The probabilistic sensitivity analyses
showed that over 72 % and 89 % of the iterations when
compared with salmeterol and tiotropium, respectively,
produced dominant results for indacaterol.
Conclusion The analyses demonstrate that indacaterol
dominates both tiotropium and salmeterol in the base case
and is likely to remain cost-effective under a range of
assumptions.
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Key Points for Decision Makers
• Indacaterol is the first once-daily long-acting beta2-
agonist (LABA) that has been shown to improve
lung-function, COPD symptoms, and health-related
quality of life (HRQoL) compared to salmeterol and
tiotropium.
• The model showed that indacaterol produced cost
savings and incremental health benefits over a range of
time frames and is therefore a cost-effective alternative
to current standard of care for the maintenance treat-
ment of moderate and severe patients with COPD.
• Uncertainty analysis showed that if decision makers
are willing to pay £20,000 per QALY gained, there is
over 80 % probability that indacaterol is cost-effective
compared to salmeterol and tiotropium.
1 Introduction
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive, chronic lung disease that is characterised by air-
flow limitation. The primary symptoms of breathlessness,
excessive sputum production, chronic cough and poor
exercise tolerance, result in chronic morbidity and mor-
tality [1]. Worldwide, by 2020, COPD is projected to rank
fifth in burden of disease [1]. In the UK it is estimated that
3 million people have the disease [2].
In addition to the health impact, COPD also poses a
great financial burden. The direct cost of COPD to the UK
healthcare system is estimated to be £810–930 million each
year and the broader impact on employers and the UK
economy is estimated to be £3.8 billion [3]. Although the
direct costs of COPD in the UK can be estimated, there is
little published evidence of the real life healthcare con-
sumption of patients in the different stages of COPD.
COPD is not curable; however there are several effec-
tive treatments available. The National Institute for Health
and Clinical Excellence (NICE) have published treatment
algorithms for the adequate management of patients with
COPD in the UK [2]. The stepwise progression of inhala-
tion therapies recommended by NICE is based on the best
available clinical and cost-effectiveness evidence and aims
to improve the standard of care for patients with COPD in
the UK [2]. NICE guidelines recommend that patients with
moderate to severe COPD initiate maintenance therapy
with a long-acting bronchodilator if short-acting bron-
chodilators are not providing sufficient symptom relief.
However there are several long-acting bronchodilators
available in the UK. Therefore, healthcare decision makers
need to understand which of the available therapies is the
most cost-effective from the NHS perspective. Indacaterol
is a relatively new once-daily long-acting beta2-agonist
(LABA) that has been shown to improve lung function,
COPD symptoms, and health-related quality of life
(HRQoL) endpoints compared with existing monotherapy
bronchodilators [4–6].
The use of real-world evidence on the resource use of
patients with COPD is valuable in accurately assessing the
cost-effectiveness of COPD treatments. The Optimum
Patient Care Research Database (OPCRD) [7] contains
anonymised research-quality data from patients attending
approximately 300 primary care practices in England and
Scotland that subscribe to OPCRD for chronic respiratory
review services. These data include longitudinal routine
clinical data extracted from practice records of over 20,000
patients with a confirmed diagnosis of COPD.
In this analysis, the effectiveness data from two 6-month
clinical trials of indacaterol [4, 5] (indacaterol 150 and
300 lg doses) have been combined with data from the
OPCRD [7] on healthcare consumption of COPD patients
in the different stages of the disease. The clinical effec-
tiveness and resource use data has been applied within an
economic model to estimate the longer term expected costs
and outcomes associated with indacaterol’s use, compared
with tiotropium and salmeterol.
1.1 Objective
The aim of this analysis is to use real world evidence of
resource use within an economic model to establish the
cost-effectiveness profile of indacaterol, the most recent
LABA to be launched in the UK, compared with the
existing once-daily long-acting muscarinic antagonist
(LAMA) tiotropium and the twice-daily LABA salmeterol,
in patients with moderate to severe COPD. The analysis
took the healthcare payer perspective.
2 Methods
2.1 Model Structure
COPD is a chronic degenerative disease with recurring
exacerbations. A Markov model provides a suitable struc-
ture to model such a disease. A Markov model comprises
discrete health states that describe the status of a patient.
Patients stay in one health state for the duration of a model
cycle, accumulating the costs and benefits associated with
that health state. At the end of a cycle, patients may remain
in a state or move to another state, according to defined
transition probabilities.
The model was developed as a global model allowing
local country adaptations to inform the cost-effectiveness
of indacaterol compared with current treatments. A
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previous publication on the cost-effectiveness of indaca-
terol in the German setting presents in detail the method-
ology used to develop the model [8]. This paper presents
the specific methods and results for the UK setting.
This analysis used a Markov model constructed in
Microsoft Excel 2007 (Microsoft, Redmond, Washington)
with four main health states describing the different COPD
severities plus a state for death. For each disease severity
state, two further health states were created for patients
who experienced a severe (requiring hospitalisation) or
non-severe exacerbation (requiring medical management in
the community), to give a total of 12 health states plus
death, as shown in Fig. 1. Mirror states were created for the
12 health states to describe the disease progression of
patients who discontinued therapy.
2.2 Model Parameters
Cycle lengths were set to 3 months in order to capture
initial lung function improvement. Forced Expiratory
Volume in 1 second (FEV1) was the primary endpoint of
the indacaterol studies and most clinical studies show that
improvement in trough FEV1 is recorded over the first
8–16 weeks of treatment. Trough FEV1 versus placebo
after 12 weeks of treatment was the primary outcome of
the indacaterol studies.
Discounting was set to 3.5 % per annum for both costs
and outcomes in line with the NICE guidelines for health
technology assessments [9]. The time horizon in an eco-
nomic evaluation should cover the full period over which
the benefits and costs of an intervention are expected to be
accumulated [9]. Although a lifetime time horizon is rec-
ommended in the UK [9]; in the base case, the analysis was
run over a 3-year period. The rationale for conducting the
analysis over a shorter period was that the relevant clinical
trials for indacaterol extended to 6 months and although it
is reasonable to expect patients to take indacaterol for
longer time periods given that COPD is a life-long, pro-
gressive illness; extrapolation of 6-month data to very long
time periods would lead to unacceptable levels of uncer-
tainty in the analysis. Several published economic evalu-
ations in COPD have also used shorter than lifetime time
horizons [10–13]. A 3-year duration was considered suffi-
cient to capture costs and benefits, given that many patients
are likely to step up or discontinue their maintenance
therapy after 3 years [14]. The results for a 5-year and
lifetime time horizon are also presented.
The model population was based on the patients enrolled
in the clinical trials who had moderate to severe COPD
(classified by post-bronchodilator FEV1 between 30 % and
80 % of the normal population), a mean age of 63.6 years,
and 67 % were male. The starting distribution in the model
reflected the baseline distribution of each trial between
health states and is presented in Table 1.
COPD guidelines recommend post-bronchodilator
measurement of FEV1 for assessment of disease severity
[1], but apart from the screening visit, these were not
available from the indacaterol trials. As a consequence, and
in line with previous economic analyses [11, 15], pre-
bronchodilator values were used to describe efficacy, util-
ities and medical resource use for the disease severity
health states. The available literature all followed the
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Fig. 1 Model schematic.
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convention of using pre-bronchodilator values to define
these data and since pre-bronchodilator values were used
for all comparators the impact on incremental results was
minimal. The cut-off points adopted in the clinical trials to
define COPD severity were the same as the Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD) [1],
which compares patient FEV1 with FEV1 for the normal
population to ascertain percentage of normal lung function.
2.3 Analysis
A cohort analysis was conducted with the Markov model,
based on a population of 1,000 patients. Expected costs and
outcomes were used to estimate a total cost, total life-years
gained, total severe and non-severe exacerbations and total
quality adjusted life-years (QALYs) gained per patient.
Incremental cost-effectiveness ratios were reported as cost
per QALY gained.
Both one-way and probabilistic sensitivity analyses
(PSA) were conducted to test the assumptions of the model
and the overall robustness of the results. Tornado diagrams
give an indication of the parameters/assumptions which are
particularly important contributors to the model’s results.
Parameters from clinical trial data were varied within the
95 % CIs and parameters for which data on uncertainty
were not available were varied by ± 30 %. For the PSA,
costs and resource use were varied according to a gamma
distribution, utilities by a beta distribution and rate ratios
by a log-normal distribution. These distributions were
stochastically sampled for 1,000 iterations and the ICER
output was recorded. The results of the PSA are shown on a
cost-effectiveness plane, where the incremental costs and
incremental QALYs for each iteration of the PSA are
plotted. The quadrant in which the ICER falls is informa-
tive of the cost-effectiveness of the treatment under
evaluation.
A threshold analysis was also conducted to assess the
impact of using lower prices for tiotropium on the cost-
effectiveness results. This is aimed to reflect the situation
when branded tiotropium loses exclusivity in the UK.
2.4 Clinical Model Inputs
Two key, 6-month trials for indacaterol informed the
clinical inputs for the model. The trials were both multi-
centre, placebo-controlled, randomised studies with active
controls [4, 5]. The INLIGHT-2 trial was a double-blind
study comparing indacaterol (Onbrez Breezhaler, Nov-
artis) 150 lg daily, salmeterol (Serevent, A&H) 50 lg
twice daily and placebo [5]; the INHANCE trial compared
indacaterol 150 or 300 lg daily with open-label tiotropium
(Spiriva, Boehringer Ingelheim) 18 lg daily [4]. Each
trial provided data on the rate of exacerbations and the
improvement in lung function (trough FEV1 at week 12
was the primary endpoint). Detailed patient characteristics
for these trials have been previously published [8].
Data from the trials using indacaterol 150 lg dose is
presented as the base case as this is the most commonly
recommended dose licensed in the UK. Patients are
allowed to increase their dose to the 300 lg dose on
medical advice, which has been shown to provide addi-
tional clinical benefit for patients with severe COPD and
therefore the results of the comparison of indacaterol
300 lg versus tiotropium 18 lg have also been presented.
Indacaterol 300 lg was not included in the trial versus
salmeterol and therefore there are no efficacy results
available to inform this comparison in the model.
2.5 FEV1 Improvement
Transition probabilities used in the model were based on
transition matrices constructed from individual patient
level data, which tracked the movement of patients over the
first 12 weeks across different disease states. This allowed
the model to fully capture change in disease states rather
than using aggregated average improvement in FEV1 lev-
els. As discussed above, the primary endpoint of the ind-
acaterol trials was FEV1 improvement at week 12 which is
a commonly used regulatory time frame cut-off for regis-
tration clinical studies. The transition matrices describing
the movement of patients over the first 12 weeks in the
INHANCE and INLIGHT-2 trials are presented in Table 2.
This transition matrix was applied to the first cycle
(12 weeks) of the model only, to describe the initial
Table 1 Patient characteristics [8]
Trial INHANCE INLIGHT-2
Study arms Indacaterol
150 lg
Indacaterol
300 lg
Tiotropium
18 lg
Indacaterol
150 lg
Salmeterol
2 9 50 lg
Length of study 26 weeks 26 weeks
Number of subjects
(randomised)
1683 998
Mean age, years
(standard deviation)
63.6 (9.1) 63.5 (8.81)
Proportion of males (%) 62.8 74.6
Duration of COPD, years
(standard deviation)
6.8 (6.75) 6.5 (5.71)
Starting disease severity distribution (%)
Mild COPD 1.4 1.2
Moderate COPD 36.7 41.3
Severe COPD 50.2 49.4
Very Severe COPD 11.69 8.1
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improvement in FEV1 after starting therapy. After the first
cycle, all patients experience a uniform lung function
decline over the model duration (Table 3).
2.6 Exacerbation Rates
The observed exacerbation rates from the placebo control
arms of the indacaterol trials were used in the model.
Annual rates in the placebo arm were similar across the
trials ranging from 0.60 to 0.74 exacerbations per patient
per year and these rates set the overall number of exacer-
bations that occurred in the model. The definition of an
exacerbation in the model was based on resource use and
differs from that of the clinical trial; severe exacerbations
were those requiring hospitalisation and non-severe were
those requiring a change in medication and/or contact with
a healthcare provider. The probability that an exacerbation
would be severe or non-severe in each of the severity
stages was based on the clinical trial data. Exacerbations
from the placebo arm of the indacaterol trials were pooled
and the most recent pre-bronchodilator FEV1 value recor-
ded before an exacerbation was used to classify the disease
severity status in which the exacerbation took place.
The treatment effect on exacerbation reduction was
described as rate ratios and based on the respective studies.
Annual rates of exacerbations for the active arms were low
in the clinical trials (typically around 0.5 per patient for all
treatments) since the study was not enriched to recruit an
exacerbating population. All rate ratios were applied to the
baseline rate of exacerbations, and therefore rate ratios
versus placebo were used. Annual exacerbation rates could
not be derived for each treatment by disease severity from
the trial data due to the small number of observed events in
each study (Table 3).
2.7 Other Clinical Inputs
A differential rate of lung function decline was not dem-
onstrated in these two studies and the rate of lung function
decline for COPD patients was therefore derived from the
UPLIFT [16] trial, which gave the annual rate of decline in
pre-bronchodilator FEV1 measurements as 30 ml per year
with a standard error of 1 ml; the UPLIFT trial is one of the
longest COPD trials conducted recently (Table 3).
Two different mortality rates were utilised in the model
in order to fully describe the death rate of a COPD popu-
lation. The first was a COPD-related mortality and the
second was an all-cause mortality rate used to account for
deaths from competing causes in the study population.
COPD-related mortality was obtained from a published
study which gave mortality rates for a COPD patient cohort
grouped by disease severity [12]. While this source
accounts for all-cause mortality within this cohort, we have
made the assumption that all deaths recorded within this
study were COPD-related, since separate measures of
COPD-attributable death by disease severity (required to
separate the types of death) were not available (Table 3).
All-cause mortality was obtained from UK interim life
tables for 2008–10 issued by the Office for National Sta-
tistics [17]. In the model, all-cause mortality was not
adjusted for COPD-specific deaths due to lack of data.
Table 2 Transition matrix (baseline to 12 weeks) from the IN-
HANCE and INLIGHT-2 trials
From
Mild Moderate Severe Very Severe
INHANCE
150 lg indacaterol
To
Mild 60.00 % 8.22 % 0.64 % 0.00 %
Moderate 40.00 % 84.25 % 38.85 % 2.63 %
Severe 0.00% 7.53% 58.60% 63.16%
Very Severe 0.00% 0.00% 1.91% 34.21%
300 lg indacaterol
To
Mild 62.50% 15.07% 0.60% 0.00%
Moderate 25.00% 78.77% 38.32% 9.09%
Severe 12.50% 5.48% 58.68% 63.64%
Very Severe 0.00% 0.68% 2.40% 27.27%
18 lg tiotropium
To
Mild 60.00% 11.11% 0.52% 0.00%
Moderate 40.00% 84.26% 30.89% 2.33%
Severe 0.00% 4.63% 64.40% 55.81%
Very Severe 0.00% 0.00% 4.19% 41.86%
INLIGHT-2
150 lg indacaterol
To
Mild 66.67% 14.29% 0.69% 0.00%
Moderate 33.33% 75.40% 27.59% 0.00%
Severe 0.00% 9.52% 68.97% 57.14%
Very Severe 0.00% 0.79% 2.76% 42.86%
2 3 50 lg salmeterol
To
Mild 75.00% 9.57% 0.00% 0.00%
Moderate 25.00% 80.87% 23.08% 0.00%
Severe 0.00% 9.57% 70.63% 53.85%
Very Severe 0.00% 0.00% 6.29% 46.15%
Reprinted from Respiratory Medicine, Vol 105, David Price, Alastair
Gray, Rupert Gale, Yumi Asukai, Laura Mungapen, Adam Lloyd,
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2.8 Economic Model Inputs
Unit costs were obtained from a combination of UK cost
sources and costs from the literature. Table 4 shows the
unit costs for all healthcare products and services used in
the model. All costs are expressed as Pounds Sterling (£)
for the cost year 2011 and have been inflated to 2011 prices
using the Hospital and Community Health Services Index
[18] where necessary. Resource use from the OPCRD [7]
and the literature was validated with a UK clinician with
expertise in COPD management.
The cost of the different disease states and exacerbations
consist of costs accrued in the community and the hospital
setting. The cost of community-based care providers were
taken from the Personal Social Services Research Unit
(PSSRU) [18] and all hospital services including ambu-
lance, admission costs, professional and lab services were
taken from the NHS reference costs 2009–2010 [19].
Drug prices were obtained from the British National
Formulary (BNF) [20]. For COPD-specific drugs, the rec-
ommended dose and package size was used to calculate the
cost per day. For the influenza and pneumococcal vaccine,
the unit cost to the Department of Health was used, which
includes the cost of the vaccine and the GP administration
fee [3]. The OPCRD [7] reports the number of prescrip-
tions for a specific drug class over a 12-month period.
Therefore for these drugs (short-acting beta-2 agonists
(SABA), short-acting antimuscarinic bronchodilator
(SAMA), inhaled corticosteroids (ICS), leukotriene recep-
tor antagonists (LTRA), theophylline, mucolytics and oral
corticosteroids), the Prescription Cost Analysis dataset
2011 [21] was used to ascertain the average cost per pre-
scription. The weighted average cost per prescription of the
five most common products in each of the drug classes was
used.
Home oxygen therapy in the UK is supplied by the
Home Oxygen Service which uses specific contractors to
supply oxygen in patients’ homes [22]. The cost of this
service was not readily available and therefore the cost per
day of oxygen therapy reported in a published cost-effec-
tiveness analysis [11] has been inflated and converted from
local currency and used in the model. NICE clinical
guidelines recommend that all very severe COPD patients
are assessed for home oxygen [2]. It is reported that
Table 3 Other model parameters
Parameter Value Range used in SA Distribution Source
Discount rate (%) 3.5 NAa NAa NICE 2009 [9]
Discontinuation rate (%) 1.73 1.24–4.88 Beta Assumptionb
Lung volume decline per year (ml) 30 28–52 Normal Tashkin et al. 2008 [16]c
Probability of progression to the next COPD
severity state
0.9 Range based on stochastic
sampling of lung volume
decline
NAa Calculated based on FEV1
decline reported in Tashkin
et al. 2008 [16]
Exacerbation rate ratio versus placebo:
indacaterol 150 lg (salmeterol analysis)
0.75 0.46–1.21d Lognormal INHANCE and INLIGHT-2
clinical trials
Exacerbation rate ratio versus placebo:
salmeterol 150 lg
0.63 0.38–1.05d Log normal INHANCE and INLIGHT-2
clinical trials
Exacerbation rate ratio versus placebo:
indacaterol 150 lg (tiotropium comparison)
0.67 0.46–0.99d Log normal INHANCE and INLIGHT-2
clinical trials
Exacerbation rate ratio versus placebo:
indacaterol 300 lg (tiotropium comparison)
0.75 0.51–1.08d Log normal INHANCE and INLIGHT-2
clinical trials
Exacerbation rate ratio versus placebo:
tiotropium 18 lg
0.70 0.48–1.03d Log normal INHANCE and INLIGHT-2
clinical trials
Probability of death due to Mild COPD 0e 0–0f Beta Rutten-van Molken 2007 [12]
Probability of death due to Moderate COPD 0.003e 0–009f Beta Rutten-van Molken 2007 [12]
Probability of death due to Severe COPD 0.006e 0–0.018f Beta Rutten-van Molken 2007 [12]
Probability of death due to Very Severe COPD 0.024e 0–0.053f Beta Rutten-van Molken 2007 [12]
a Variable not included in sensitivity analysis
b Calculated based on an assumption of an annual discontinuation rate of 7 % that varies between 5 % and 20 %
c Standard error reported in Tashkin et al. 2008 [16] was used to estimate the range used in the sensitivity analyses
d Sensitivity analyses range based on 95 % confidence interval
e Values from Rutten-van Molken [12] have been adjusted for the 3-month model cycle length
f Sensitivity analyses range based on 95 % confidence interval for the rate of exacerbations from the indacaterol clinical trials
COPD chronic obstructive pulmonary disease, NA not available, SA sensitivity analyses
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approximately 40 % of very severe COPD patients should
be on home oxygen, however currently it is believed that
only half of those who require home oxygen receive it [3].
In the base case, it is assumed that all patients who require
home oxygen receive it (i.e. 40 % of very severe COPD
patients [3] and 5 % of severe COPD patients).
There was limited evidence on the cost of delivering
pulmonary rehabilitation to COPD patients in the UK. The
cost estimate used in the model was taken from a report by
the Department of Health on the development of a national
strategy for COPD services [3].
This analysis used real-life resource use from the OP-
CRD [7]. Of the over 28,000 COPD subjects in the data-
base, 20,001 patients had a confirmed diagnosis with an
FEV1/Forced Vital Capacity (FVC) ratio \ 0.7. Using the
20,001 subjects, the average use of concomitant medica-
tions (SABA, SAMA, ICS, LTRA, theophylline, muco-
lytics and oral corticosteroids), pulmonary rehabilitation
and GP consultations related to COPD were calculated for
each of the COPD GOLD stages. Resource use data not
available in the OPCRD [7] (respiratory specialist visits,
and spirometry) were taken from the literature [11].
Table 5 shows the resource utilization rates for the health
states that were applied in the model.
Resource use associated with exacerbations was
unavailable from the OPCRD [7] and therefore are based
on assumptions that have been validated by a clinician. For
a non-severe exacerbation, it was assumed that all patients
visited the GP once, and 50 % took antibiotics and oral
corticosteroids for 7 days and 50 % took these therapies for
14 days (an average of 10.5 days for all patients). For
severe exacerbations it was assumed that 70 % of patients
arrived at hospital in an ambulance before they were
admitted. In addition it was assumed that patients took
antibiotics and oral corticosteroids for 10.5 days (Table 6).
2.9 Utility Inputs
European Quality of Life – five dimensions (EQ-5D) is a
standardised questionnaire used to measure HRQoL and
allows the calculation of a utility value for a specific health
state [23]. EQ-5D data were collected in the three ind-
acaterol phase III clinical trials at the start of the studies, at
week 12 (primary endpoint) and at week 26 (end of the
studies) [24]. In the indacaterol trials, whenever an EQ-5D
questionnaire was completed at a time for which a pre-
bronchodilator FEV1 value was available, the EQ-5D score
was labelled as describing the corresponding disease
Table 4 Cost for health care
products and services used in
the model
a During exacerbations
BNF British national formulary,
COPD chronic obstructive
pulmonary disease, GP general
practitioner, ICS inhaled
corticosteroids, LTRA
leukotriene receptor antagonist,
NHS National Health Service,
PCA prescription cost analysis,
PSSRU personal social services
research unit, SABA short-acting
beta-2 agonists, SAMA short-
acting antimuscarinic
bronchodilator
Item Cost (£) Source
Health care services
GP visit 36.00 PSSRU 2011 [18]
Outpatient respiratory specialist visit 134.61 NHS Reference Costs 2009–10 [19]
Physiotherapist (per hour) 34.00 PSSRU 2011 [18]
Spirometry 51.38 NHS Reference Costs 2009–10 [19]
Hospitalisation for COPD exacerbation 1693.40 NHS Reference Costs 2009–10 [19]
Ambulance transportation to emergency 239.42 NHS Reference Costs 2009–10 [19]
Pulmonary rehabilitation 1017.27 Department of Health 2010 [3]
Home oxygen therapy (per day) 15.33 Oostenbrink et al. 2005 [11]
Drug
Indacaterol 150 lg (daily) 0.98 BNF 62 [20]
Indacaterol 300 lg (daily) 0.98 BNF 62 [20]
Tiotropium 18 lg (daily) 1.06 BNF 62 [20]
Salmeterol 2 9 50 lg (daily) 0.98 BNF 62 [20]
Theophylline (per script) 3.43 PCA 2011 [21]
Mucolytics (per script) 21.85 PCA 2011 [21]
Oral corticosteroids (per script) 8.79 PCA 2011 [21]
SABA (per script) 5.98 PCA 2011 [21]
ICS (per script) 12.12 PCA 2011 [21]
SAMA (per script) 10.24 PCA 2011 [21]
LTRA (per script) 31.77 PCA 2011 [21]
Influenza vaccination (per administration) 14.20 Department of Health 2010 [3]
Pneumococcal vaccination (per administration) 46.75 Department of Health 2010 [3]
Oral corticosteroids, 30 mga (per day) 0.58 BNF 62 [20]
Antibioticsa (per day) 0.98 PCA [21]; BNF 62 [20]
Cost-Utility Analysis of Indacaterol in the UK 265
severity health state. Over 11,000 EQ-5D questionnaires
were pooled and analysed to describe the HRQoL for the
COPD disease severity health states. Although the EQ-5D
data were collected from subjects across 21 different
countries, the UK National Health Survey preference
weights was used to value the utility score [24, 25].
No utility data were available from the trials to describe
an exacerbation and therefore values from a published
study which measured the disutility associated with an
exacerbation was used [26]. This study recruited partici-
pants from the general population in the Netherlands and
aimed to include subjects who represented the Dutch
population in terms of age, sex and education level [26].
Participants were asked to value several COPD health
profiles using both the visual analogue scale and the time
trade-off method [26]. The utility decrements for COPD
exacerbations reported using the time trade-off methodol-
ogy was used in the model (Table 7).
3 Results
3.1 Cost-Utility Analysis
The deterministic cost-effectiveness results for the com-
parison of indacaterol 150 lg daily to tiotropium 18 lg
daily and salmeterol 50 lg twice daily over a 3-year time
horizon are summarized in Table 8. In comparison with
salmeterol and tiotropium, indacaterol results in a per-
patient cost savings of approximately £110 and £248
Table 5 Resource utilisation for model health states
Annual resource
utilisation for
maintenance
Mild Range
used in SA
Moderate Range used
in SA
Severe Range used
in SA
Very
Severe
Range used
in SA
Distribution Source
Influenza
vaccination
0.73 0.53–0.93a 0.73 0.53–0.93a 0.73 0.53–0.93a 0.73 0.53–0.93a Beta Department of
Health/HPA
2011 [32]
Pneumococcal
vaccination
0.69 0.49–0.89a 0.69 0.49–0.89a 0.69 0.49–0.89a 0.69 0.49–0.89a Beta Department of
Health [3]
Theophylline
(number of
scripts)
0.26 0.18–0.34b 0.32 0.22–0.41b 0.73 0.51–0.95b 1.63 1.14–2.11b Gamma OPCRD 2012 [7]
Mucolytics (number
of scripts)
0.35 0.24–0.45b 0.40 0.28–0.52b 0.80 0.56–1.05 2.05 1.43–2.66 Gamma OPCRD 2012 [7]
Oral corticosteroids
(number of
scripts)
0.88 0.61–1.14b 0.96 0.67–1.25b 1.70 1.19–2.21 2.70 1.89–3.52b Gamma OPCRD 2012 [7];
clinical opinion
SABA (number of
scripts)
3.74 2.62–4.86b 4.65 3.25–6.04b 6.87 4.81–8.93b 9.78 6.85–12.71b Gamma OPCRD 2012 [7]
ICS (number of
scripts)
0.89 0.62–1.16b 0.81 0.57–1.05b 0.71 0.50–0.93b 0.62 0.44–0.81b Gamma OPCRD 2012 [7]
SAMA (number of
scripts)
0.59 0.41–0.77b 0.65 0.46–0.85b 0.91 0.64–1.19b 1.19 0.84–1.55b Gamma OPCRD 2012 [7]
LTRA (number of
scripts)
0.00 0b 0.00 0b 0.37 0.26–0.48b 0.00 0b Gamma OPCRD 2012 [7]
Pulmonary
rehabilitation
0.02 0.02–0.03b 0.03 0.02–0.04b 0.06 0.04–0.08b 0.09 0.06–0.12b OPCRD 2012 [7]
Home oxygen
therapy
(proportion of
patients)
0.00 0b 0.00 0b 0.05 0.04–0.07b 0.40 0.28–0.52b Beta Clinical opinion;
Department of
Health [3]
GP visits 15.05 10.54–19.57b 15.76 11.03–20.48b 16.20 11.34–21.05b 16.16 11.31–21.01b Gamma OPCRD 2012 [7]
Outpatient
respiratory
specialist visit
0 0b 0 0b 2 1.40–2.60b 4 2.8–5.2b Gamma Oostenbrink et al.
2005 [11]
Spirometry (number
of tests)
1 0.7–1.3b 2 1.4–2.6b 2 1.4–2.6b 4 2.8–5.2b Gamma Oostenbrink et al.
2005 [11]
Resource utilisation was validated by a UK clinician
a Sensitivity analyses range varied by ± 20 % based on assumption; bSensitivity analyses range varied by ± 30 % based on assumption
COPD chronic obstructive pulmonary disease, GP general practitioner, HPA health protection agency, ICS inhaled corticosteroids, LTRA leukotriene receptor
antagonist, OPCRD optimum patient care research database, SA sensitivity analyses, SABA short acting beta-2 agonists, SAMA short acting antimuscarinic
bronchodilator
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respectively and produces improved outcomes. This results
in indacaterol being in a position of dominance against
both comparators.
The INHANCE trial included a comparison of indacaterol
300 lg daily against tiotropium 18 lg daily. This compari-
son also results in lower costs and improved benefits for the
indacaterol treatment group, also resulting in a position of
dominance (Table 8). The cost-utility results for the 5-year
and lifetime time horizons are presented in Table 9.
3.2 Other Health Outcomes
In addition to HRQoL, the model also estimated the
amount of exacerbations and mortality over the time
horizon. Over the 3-year time horizon, approximately 10 %
of patients receiving indacaterol had died compared with
10.8 % of patients receiving salmeterol and 10.4 %
receiving tiotropium. Over the same time frame, indaca-
terol patients experienced 1.21 non-severe exacerbations
and 0.09 severe exacerbations. In comparison, the salme-
terol and tiotropium patients experienced 1.14 and 1.30
non-severe exacerbations respectively and 0.09 severe
exacerbations.
3.3 Sensitivity Analyses
The results of one-way sensitivity analyses for indacaterol
versus salmeterol and tiotropium are summarised in a
Table 6 Resource utilisation for exacerbations
Resource utilisation per episode Non-severe
exacerbation
Range used
in SA
Severe
exacerbation
Range used
in SA
Distribution Source
Oral corticosteroids (days of treatment) 10.50 7–14a 10.50 7–14a Gamma Clinical opinion
Antibiotics (days of treatment) 10.5 7–14a 10.5 7–14a Gamma Clinical opinion
GP visits 1 0.7–1.3a 0 0 Gamma Clinical opinion
Hospitalization 0 0 1 NAb NA Assumption
Ambulance transportation to
emergency (proportion of patients)
0 0 0.7 0.49–0.91c Beta Clinical opinion
a Clinical opinion suggests drug taken for between 7–14 days
b Not included in the sensitivity analyses as a hospital admission is part of the definition of a severe exacerbation
c Sensitivity analyses range varied by ± 30 % based on assumption
GP general practitioner, NA not available, SA sensitivity analyses
Table 7 Utility values
Utility value Range used in SA Distribution Source
Stable health state
Mild 0.82 0.8–0.84 Beta Pooled indacaterol clinical trials [24]
Moderate 0.80 0.79–0.81 Beta Pooled indacaterol clinical trials [24]
Severe 0.77 0.77–0.78 Beta Pooled indacaterol clinical trials [24]
Very Severe 0.74 0.73–0.76 Beta Pooled indacaterol clinical trials [24]
Exacerbations Utility decrement Source
Non-severe exacerbation 0.01 0–0.024 Beta Rutten-van Molken et al. 2009 [26]
Severe exacerbation 0.042 0.024–0.060 Beta Rutten-van Molken et al. 2009 [26]
SA sensitivity analyses
Table 8 Cost-effectiveness results for indacaterol for a 3-year time
horizon
Indacaterol
150 lg
Tiotropium
18 lg
Difference
Total costs £4534 £4781 -£248
Total QALYs 2.158 2.150 0.008
ICER Dominanta
Indacaterol
150 lg
Salmeterol
2 3 50 lg
Difference
Total costs £4583 £4692 -£110
Total QALYs 2.158 2.149 0.008
ICER Dominanta
Indacaterol
300 lg
Tiotropium
18 lg
Difference
Total costs £4501 £4760 -£259
Total QALYs 2.162 2.151 0.011
ICER Dominanta
a Dominant = less cost, better outcomes
ICER incremental cost-effectiveness ratio, QALY quality-adjusted
life-years
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tornado diagram in Figs. 2 and 3 respectively. In both
comparisons with salmeterol and tiotropium, indacaterol
was dominant, and therefore a tornado diagram will show
negative ICERs which are not interpretable. However one-
way analyses were conducted in both cases and plotted on a
tornado diagram to ascertain the parameters with the most
significant impact on the results.
In both comparisons, the variable producing the highest
ICER was the proportion of the cohort in the different stages
of the disease. The base-case model cohort consisted of the
proportion of subjects in the different stages of COPD as
observed in the clinical trial. When it was assumed that all
subjects started in the Moderate COPD stage, the ICER was
approximately £72,894 and £3,537 per QALY in the com-
parison against salmeterol and tiotropium respectively. The
lung function benefit in the model has the impact of indi-
rectly slowing down the progression of disease, and the cost
savings in the model are as a result of slowing the pro-
gression of patients to the Severe and Very Severe COPD
stages. However, when all subjects start with Moderate
COPD and the model is run for a 3-year time horizon, there
is insufficient time to realise the full benefits of slowing the
progression of the disease to the more severe COPD states.
The other variable that had a notable impact on the
results for both comparisons was the mortality rate
associated with the Very Severe COPD health state.
Slowing the progression to more severe COPD states also
has the benefit of keeping subjects in health states with
lower mortality rates. Mortality rates for all disease
severity states were tested; however, indacaterol remained
the dominant treatment.
The PSA shows that over 72 % of iterations in the
salmeterol comparison and over 89 % of iterations in the
tiotropium comparison appear in the south east quadrant of
the cost-effectiveness plane, indicating that indacaterol was
dominant in the majority of PSA iterations in both com-
parisons (Fig. 4). A cost-effectiveness acceptability curve
(CEAC) (Fig. 5) shows the probability that an intervention
is cost-effective at different thresholds for the willingness
to pay for a QALY gained. At a willingness-to-pay
threshold of £20,000 per QALY gain, the probability that
indacaterol is cost-effective is approximately 82 % and
84 % for the comparisons with salmeterol and tiotropium
respectively. The CEAC curve plateaus at approximately
89 % for both comparisons. This is due to the small per-
centage of PSA iterations that resulted in inferior or
dominated results (values in the northwest and southwest
quadrants in Fig. 4).
The threshold analysis consisted of running the analysis
for various percentage reductions on the price of tiotropium
Table 9 Cost-effectiveness
results for indacaterol using a
5-year and lifetime time horizon
a Dominant = less cost, better
outcomes
ICER incremental cost-
effectiveness ratio, QALY
quality-adjusted life-years
5-year time horizon
Indacaterol 150 lg Tiotropium 18 lg Difference
Total costs £7102 £7457 -£355
Total QALYs 3.357 3.340 0.016
ICER Dominanta
Indacaterol 150 lg Salmeterol 50 lg twice daily Difference
Total costs £7174 £7330 -£155
Total QALYs 3.357 3.339 0.018
ICER Dominanta
Indacaterol 300 lg Tiotropium 18 lg Difference
Total costs £7054 £7427 -£374
Total QALYs 3.367 3.344 0.023
ICER Dominanta
Lifetime time horizon (20 years)
Indacaterol 150 lg Tiotropium 18 lg Difference
Total costs £17189 £17720 -£532
Total QALYs 7.873 7.795 0.078
ICER Dominanta
Indacaterol 150 lg Salmeterol 50 lg twice daily Difference
Total costs £17270 £17485 -£215
Total QALYs 7.866 7.773 0.093
ICER Dominanta
Indacaterol 300 lg Tiotropium 18 lg Difference
Total costs £17,104 £17,682 -£579
Total QALYs 7.929 7.810 0.119
ICER Dominanta
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Fig. 3 Tornado diagram (indacaterol 150 lg versus tiotropium
18 lg). ^Low value for the mortality rate was 0 % for all severities.
The high value was Moderate COPD 0.89 %, Severe COPD 1.78 %
and Very Severe COPD 5.34 %. *Low value for the utility was Mild
COPD 0.80, Moderate COPD 0.79, Severe COPD 0.77 and Very
Severe COPD 0.73. The high value for the utility was Mild COPD
0.84, Moderate COPD 0.81, Severe COPD 0.78 and Very Severe
COPD 0.76. CI confidence interval, COPD chronic obstructive
pulmonary disease, FEV1 forced expiratory volume in 1 second,
M moderate, NS non-severe, S severe, VS very severe
Fig. 2 Tornado diagram (indacaterol 150 lg versus salmeterol
2 9 50 lg). ^Low value for the mortality rate was 0 % for all
severities. The high value was Moderate COPD 0.89 %, Severe
COPD 1.78 % and Very Severe COPD 5.34 %. *Low value for the
utility was Mild COPD 0.80, Moderate COPD 0.79, Severe COPD
0.77 and Very Severe COPD 0.73. The high value for the utility was
Mild COPD 0.84, Moderate COPD 0.81, Severe COPD 0.78 and Very
Severe COPD 0.76. CI confidence interval, COPD chronic obstructive
pulmonary disease, FEV1 forced expiratory volume in 1 second,
M moderate, NS non-severe, S severe, VS very severe
Cost-Utility Analysis of Indacaterol in the UK 269
after 1 year of the model time horizon. The results showed
that for up to a 41 % reduction on the price of branded
tiotropium (a daily cost of £0.63 compared with £1.06 in
the base case), indacaterol remained the dominant strategy.
In over 43 % of the PSA iterations, indacaterol was the
dominant strategy (data not shown) and at a willingness-to-
Fig. 4 Cost-effectiveness plane
Fig. 5 Cost-effectiveness acceptability curve
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pay threshold of £20,000 per QALY gain, there was over
76 % probability that indacaterol is cost-effective (data not
shown).
3.4 Model Validation
The model results were compared with other studies and
reviewed by an external health economist to validate its
structure. Comparisons of life expectancy with several
epidemiology sources for COPD patients [27, 28] as well
as statistics from the US Center of Disease Control and
Prevention (CDC) showed that mortality rates in the model
were similar. Model inputs and outputs were also compared
with existing economic evaluations [12, 29] and found to
be comparable.
4 Discussion
Clinical trials have shown that compared with both
salmeterol and tiotropium, indacaterol results in greater
lung volume improvements after 12 weeks of treatment [4,
5]. This clinical benefit allowed patients within the model
to improve their disease severity classification in the first
model cycle. This results in a larger proportion of patients
in the indacaterol treatment arm initially improving to a
milder disease state and therefore enjoying a better quality
of life, lower costs and a slower progression to more severe
states compared with those that don’t benefit from the
initial change to a milder disease state. This benefit was the
key driver to producing ICERs which were dominant
against both comparators.
The INHANCE trial included a comparison of indaca-
terol 300 lg daily against tiotropium 18 lg daily. The
increased dosage of indacaterol has been shown to produce
increased benefits, and can be prescribed for patients with
severe COPD. In addition to the increased benefits, in the
UK indacaterol 300 lg daily has the same price as ind-
acaterol 150 lg daily, resulting in the increased dose also
being dominant against tiotropium.
The indacaterol studies did not recruit patients on the
basis of exacerbations and therefore there was a low rate of
exacerbations across these trials. The trials showed a
similar positive trend between all active treatments in
comparison with placebo in preventing exacerbations
however, the rate ratios from the trial which directly
compared indacaterol with other bronchodilators all con-
tain 1.0 in the confidence interval, thus making the results
statistically non-significant. The model output for exacer-
bations resulted in patients in the tiotropium treatment arm
having slightly more, and patients in the salmeterol arm
having slightly fewer exacerbations than those in the ind-
acaterol treatment group.
The one-way sensitivity analyses highlighted the
importance of the input values for mortality rates on the
results. Although no mortality benefit was assumed with
any treatment, the differential mortality rates by disease
severity combined with the improvement in lung function,
which indirectly slowed progression to more severe COPD
states which have higher mortality rates, also bestowed an
indirect mortality benefit.
The composition of the model population also had a
significant impact on the results. When it was assumed that
the model consisted of only moderate COPD patients, the
ICER increased. As a result of having a 100 % moderate
starting population, fewer subjects improve to a less severe
disease state compared with patients starting in the severe
disease state.
Another determinant of cost-effectiveness was the time
horizon of the model. Extending the time horizon from
3 years to longer timeframes reduces the ICER. This is
because the model assumed that the FEV1 benefit incurred
at the beginning of treatment will not be lost over the
course of the lifetime, that is, the slope of lines describing
lung function decline will remain parallel between treat-
ment groups until death. Other studies have shown that the
initial FEV1 improvement can last up to 3 years [30]
however the maintenance of benefit has not been demon-
strated in longer term studies. This assumption resulted in
indacaterol patients remaining in milder disease states for
longer and benefiting from the indirect mortality benefit
over an extended timeframe.
It is expected that when branded tiotropium loses
exclusivity in the UK, the cost of tiotropium will reduce,
however the extent of the price reduction is unknown.
The threshold analysis showed that if the cost of tiotropium
was discounted by up to 41 % after 1 year of the model
time horizon, indacaterol would remain the dominant
strategy.
The majority of the resource utilisation data for the
different health states in the model were taken from real
world evidence of resource consumption by COPD patients
in the UK. The use of the OPCRD [7] ensures the model
reflects current clinical practice without which the results
would be based on assumptions and estimations.
These results indicate that all doses of indacaterol can
produce better outcomes at a lower cost to the healthcare
system compared with current treatments. Although there
was no clinical data to support a comparison of indacaterol
300 lg with salmeterol, given that the daily cost of both
indacaterol formulations are the same; the cost-effective-
ness results are likely to be similar or better than the
comparison with indacaterol 150 lg. In the context of
currently available treatments for the maintenance therapy
of COPD, indacaterol provided a cost-effective alternative
to the current standard of care.
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4.1 Limitations
Limitations can arise from the model structure, model
assumptions and data inputs. A limitation of Markov
models is that it is not possible to record the history of a
patient and therefore it cannot keep track of patients who
discontinue treatment. Those who discontinue no longer
benefit from the improvement in lung function from the
active therapy. The trial data showed that discontinuation
rates were similar among all three interventions, justifying
the assumption in the model of equal discontinuation rates
for all active treatments.
The key model assumption that lung function improvement
changes COPD disease severity and therefore results in an
implicit mortality benefit is a limitation of the model, as the
clinical trials do not demonstrate this as an endpoint. However
previous COPD models have set precedence for modelling
lung function improvement in this way [11, 12, 29]. In addi-
tion, there is little evidence illustrating the relationship
between change in lung function and change in health status
[1]. In this model, improved lung function is assumed to lead
to a change in health status as a result of a change in COPD
disease severity.
Model inputs were taken from several sources including
clinical trials, published and grey literature, and a clinical
practice database. The incorporation of several sources
results in the use of data derived from different and pos-
sibly inconsistent methodologies. However the impact on
the ICER results were minimised by using a consistent
source for the equivalent model input across all treatments
arms.
There were some limitations with the use of the OPCRD
database [7]. The OPCRD only captures medical data
recorded in GP practices. Therefore any resource use pre-
scribed by specialists was incompletely recorded. Since the
more severe COPD patients are more likely to be treated by
a specialist, the cost of managing the more severe health
states may be underestimated.
As with most RCTs, patients with unstable co-morbid-
ities were excluded from the study. Therefore the gener-
alisability of these results is limited to the patient
population of the indacaterol clinical trials. There is some
evidence that patients with COPD also suffer from several
co-morbidities and patients with more severe COPD may
also have more numerous and severe co-morbid conditions
[1, 31]. Although this is not reflective of real world evi-
dence, the inclusion/exclusion criteria applied equally to all
treatment arms and therefore should not bias the ICER.
However a greater understanding of the impact of co-
morbidities in the COPD population may lead to a more
accurate estimate.
The clinical data used in this model were derived from
trials of 6-month duration and therefore a limitation of the
analysis is the uncertainty introduced in extrapolating these
data to the 3-year base-case period and the longer time
horizons assessed. Real world evidence or analyses based
on trials with a longer duration are recommended to vali-
date the model’s longer-term projections in the future.
Clinical studies of 6-month durations may also not
sufficiently capture seasonal variation with regard to
exacerbation rates and therefore a model based on these
may not be generalisable to real-world exacerbation rates.
However recruitment in the studies was spread out such
that the total observation period spanned more than
6 months and was conducted in both the northern and
southern hemispheres.
These studies also had a very low overall rate of exac-
erbations observed and are not the ideal data source for
exacerbations, but are the best data to describe the exac-
erbation benefits of indacaterol currently available. More
clinical trial data addressing the exacerbation benefit is
expected to be reported later in 2013. To test the uncer-
tainty of the clinical evidence, these parameters are inclu-
ded in the one-way and probabilistic sensitivity analyses.
Given the very low and very similar rates of exacerbation
between the comparators, disabling the exacerbation
parameters had very little impact on the results.
5 Conclusion
The current cost-utility analysis combined real-world evi-
dence with clinical trial data to compare indacaterol with
tiotropium and salmeterol for use as maintenance treatment
for COPD in the UK. The analysis demonstrated that ind-
acaterol dominates in both comparisons and is likely to
remain cost-effective under a range of assumptions. The
comparison of indacaterol 300 lg with tiotropium shows
that the higher-dose form is still well positioned to dem-
onstrate cost-effectiveness. As a potential first-line main-
tenance treatment for moderate and severe COPD patients,
indacaterol is a cost-effective alternative to current stan-
dard of care.
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